Showing 2631-2640 of 10236 results for "".
DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesThe Google+ Hangout: A Marketing Tool For Your Dermatology Practice
https://practicaldermatology.com/topics/practice-management/the-google-hangout-a-marketing-tool-for-your-dermatology-practice/21423/Dermatology marketers can employ this tool effectively to promote their practices or simply use it as a powerful and free communication tool.PR Is the Next Big Thing for Online Dermatology Marketing
https://practicaldermatology.com/topics/practice-management/pr-is-the-next-big-thing-for-online-dermatology-marketing/22954/Dermatology marketers should evaluate current SEO to make room for public relations strategies.Filler Pearls: Refining the Art of Injection
https://practicaldermatology.com/topics/general-topics/filler-pearls-refining-the-art-of-injection/21683/Pain control is essential to treatment success with dermal fillers. Here's an update on pain management and other tactics to ensure patient comfort and optimize outcomes.Lip Lifts: A Procedure to Consider
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/lip-lifts-a-procedure-to-consider/23033/Consider referring for a surgical lip lift when fillers don’t suffice.Psoriasis Treatment in 2025: More Options, Better Outcomes
https://practicaldermatology.com/issues/august-2025/psoriasis-treatment-in-2025-more-options-better-outcomes/36706/We have better drugs to treat psoriasis than almost any other dermatologic disease state. For patients, it is an excellent time to have psoriasis.First Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingEverything Old Is New Again: Re-assessing IPL
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/everything-old-is-new-again-re-assessing-ipl/23013/Long-term IPL use may turn the tables on aging skin.Impetigo: An Unconventional Case Report
https://practicaldermatology.com/topics/rare-disease/impetigo-an-unconventional-case-report/26246/Mauri Hart, a medical student at the Oklahoma State University College of Osteopathic Medicine, takes a look at a unique case study, and tests the reader's knowledge of impetigo.How Physicians Are Unlike Most US Investors
https://practicaldermatology.com/topics/practice-management/how-physicians-are-unlike-most-us-investors/23370/A look at how the difference in the tax situations of physicians and average retail investors, and why these differences matter.